Autologous anti-CD19 CAR T cells 19(T2)28z1xx

{
  "id": "MLC-T-ONC-011353",
  "term": "Autologous anti-CD19 CAR T cells 19(T2)28z1xx",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-T cells 19(T2)28z1xx specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B cells. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR-T cells. The 19(T2)28z1xx CAR-T cells include a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion.",
  "synonyms": [
    "19(T2)28z1xx",
    "autologous 19(T2)28z1xx CAR T cells",
    "autologous anti-CD19 CAR-T cells 19(T2)28z1xx",
    "autologous CD19-targeted CAR-T cells 19(T2)28z1xx"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-car-t-cells-19-t2-28z1xx/"
}